Evidence map›Paper›PMID 37902399›Full record

Trial reportJournal of virology2023

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.

Yannic C Bartsch, Deniz Cizmeci, Dansu Yuan, Nickita Mehta, Jeroen Tolboom, Els De Paepe, Roy van Heesbeen, Jerald Sadoff, Christy A Comeaux, Esther Heijnen and 3 more

Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Yannic C BartschRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.ORCID 0000-0002-3844-3056
Deniz CizmeciRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Dansu YuanRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Nickita MehtaRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Jeroen TolboomJanssen Vaccines & Prevention B.V. , Leiden, South Holland, the Netherlands.
Els De PaepeJanssen Infectious Diseases , Beerse, Belgium.
Roy van HeesbeenJanssen Vaccines & Prevention B.V. , Leiden, South Holland, the Netherlands.
Jerald SadoffJanssen Vaccines & Prevention B.V. , Leiden, South Holland, the Netherlands.
Christy A ComeauxJanssen Vaccines & Prevention B.V. , Leiden, South Holland, the Netherlands.
Esther HeijnenJanssen Vaccines & Prevention B.V. , Leiden, South Holland, the Netherlands.
Benoit CallendretJanssen Vaccines & Prevention B.V. , Leiden, South Holland, the Netherlands.
Galit AlterRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Arangassery Rosemary BastianJanssen Vaccines & Prevention B.V. , Leiden, South Holland, the Netherlands.
Janssen (Netherlands) · NLRagon Institute of MGH, MIT and Harvard · USJanssen (Belgium) · BE

Funding

Janssen Pharmaceuticals
6 · The paper itself

Abstract

importanceRespiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine.

Indexed as

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAgedAntibodies, NeutralizingAntibodies, ViralHumansImmunoglobulin Fc FragmentsRespiratory Syncytial Virus, HumanViral Fusion ProteinsAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Fc FragmentsRespiratory Syncytial Virus VaccinesViral Fusion ProteinsFc-effector functionsfunctional antibodiesrespiratory syncytial virusvaccines

Identifiers

PMID37902399
PMCPMC10688327
OpenAlexW4388013884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.